Insider Selling: Beigene, Ltd. (NASDAQ:ONC) CEO Sells 101,000 Shares of Stock

Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler sold 101,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $244.30, for a total value of $24,674,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Beigene Trading Up 1.9 %

NASDAQ:ONC traded up $4.90 during mid-day trading on Wednesday, hitting $262.21. The company had a trading volume of 567,803 shares, compared to its average volume of 455,367. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene, Ltd. has a 1 year low of $126.97 and a 1 year high of $287.88. The firm has a market capitalization of $25.66 billion, a PE ratio of -31.82, a price-to-earnings-growth ratio of 7.73 and a beta of 0.63.

Beigene (NASDAQ:ONC) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). The firm had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. Research analysts predict that Beigene, Ltd. will post -5.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ONC shares. Bank of America upgraded Beigene from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $207.00 to $320.00 in a report on Monday. Macquarie raised their price target on shares of Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a report on Friday, February 28th.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.